Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of LYC-30937-EC in active ulcerative colitis
NL-OMON42876Phase 2Active, not recruiting
- Sponsor
- Lycera
- Start
- Apr 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of parimifasor in autoimmune colitis, sponsored by Lycera. Started Apr 2017; status: active, not recruiting.
02
Drugs
parimifasor
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON42876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42876.